-New features include compatibility with SureSigns VS4 spot check monitors and connectivity with the Wearable Biosensor
-The IntelliVue Guardian Solution directing caregiver attention to early signs of potential deteriorations can help reduce costly resuscitation efforts or possible transfers to the ICU
AMSTERDAM, Oct. 4, 2016 /PRNewswire/ -- Royal Philips (NYSE: PHG AEX: PHIA) today announced the latest version of the IntelliVue Guardian software, designed to aid clinicians in the early recognition of subtle signs of patient deterioration in the general care ward. This software can notify caregivers to early signs of potential degradation, which can help reduce costly complications, unplanned transfers back to the intensive care unit and longer lengths of stay in the hospital.
This new iteration of the IntelliVue Guardian software (510(k) pending – not for sale in USA) is configurable to most institutions' Early Warning Scoring protocols, and includes new features, such as compatibility with the SureSigns VS4 spot check monitors, and the IntelliVue MP5SC monitor. The IntelliVue Guardian software provides caregivers in general care wards with direct access to an automated scoring system that can be based on individual hospital policy.
The IGS Software is designed to help improve patient care, financial outcomes and clinician workflow by facilitating early intervention with Early Warning Score calculations. Having automated tools that provide a comprehensive view into a patient's condition helps enhance workflow efficiencies, simplify the medical documentation process and better utilize limited staff resources.
The new IntelliVue Guardian software can also be used with the Philips Wearable Biosensor, (510(k) pending – not for sale in USA), a medical-grade, self-adhesive, single patient-use wireless device worn discreetly on the chest. The biosensor automatically and continuously measures heart rate, respiratory rate, posture, and detects falls, and this data will can be transmitted to the IntelliVue Guardian software, which analyzes the combined trends of the measurements over a configurable period of time and notifies the appropriate caregiver or clinician when preset limits are exceeded. It provides caregivers with peace of mind that their patients are being monitored frequently for signs of deterioration between spot checks while they are attending to other tasks. The wireless Biosensor provides patients with freedom of mobility.
"Studies have shown that signs of clinical instability typically occur six to eight hours prior to a potential deterioration and that the most common predictors of this deterioration are changes in respiratory and heart ratei," said Dr. Carla Kriwet, CEO Patient Care & Monitoring Solutions. "The IntelliVue Guardian software—in tandem with the Wearable Biosensor—allows for the continuous and automatic collection and transmission of information to help caregivers recognize these signs of instability earlier, before a deterioration can occur."
The latest release of IGS software supporting the Wearable Biosensor will be available from 05 October 2016 to countries requiring the CE Mark. This release is pending FDA 510(k) clearance and is not for sale in the U.S. It will expand on Philips' continuing commitment and leadership in patient monitoring across the care continuum. The IntelliVue Guardian software will be demonstrated at Philips booth #408 at the 29th European Society of Intensive Care Medicine (ESICM) Annual Congress in Milan from October 1-5, 2016.
For further information, please contact:
Philips Group Communications
Tel: +1 978-659-2638
Mobile: +1 978-221-8919
About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
iDevita MA, Bellomo R, Hillman K, et al. Findings of the first consensus conference on medical emergency teams. Crit Care Med 2006;34:2463–78
SOURCE Royal Philips